ID | 60824 |
フルテキストURL | |
著者 |
Tomoda, Takeshi
Department of Gastroenterology and Hepatology, Okayama University Hospital
ORCID
Kato, Hironari
Department of Gastroenterology and Hepatology, Okayama University Hospital
ORCID
Kaken ID
researchmap
Miyamoto, Kazuya
Department of Gastroenterology and Hepatology, Okayama University Hospital
Matsumi, Akihiro
Department of Gastroenterology and Hepatology, Okayama University Hospital
Ueta, Eijiro
Department of Gastroenterology and Hepatology, Okayama University Hospital
Fujii, Yuuki
Department of Gastroenterology and Hepatology, Okayama University Hospital
Saragai, Yousuke
Department of Gastroenterology and Hepatology, Okayama University Hospital
Yamazaki, Tatsuhiro
Department of Gastroenterology and Hepatology, Okayama University Hospital
Uchida, Daisuke
Department of Gastroenterology and Hepatology, Okayama University Hospital
ORCID
Kaken ID
researchmap
Matsumoto, Kazuyuki
Department of Gastroenterology and Hepatology, Okayama University Hospital
ORCID
Kaken ID
publons
Horiguchi, Shigeru
Department of Gastroenterology and Hepatology, Okayama University Hospital
Tsutsumi, Koichiro
Department of Gastroenterology and Hepatology, Okayama University Hospital
ORCID
Kaken ID
researchmap
Okada, Hiroyuki
Department of Gastroenterology and Hepatology, Okayama University Hospital
Kaken ID
publons
researchmap
|
抄録 | Background
Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP). Rectal administration of non‐steroidal anti‐inflammatory drugs (NSAIDs) decreases the incidence of post‐ERCP pancreatitis (PEP). However, the efficacy of low dose rectal NSAIDs for preventing PEP remains controversial.
Methods
We performed a retrospective study of 301 patients with native papilla and a body weight of <50 kg who underwent ERCP between September 2010 and October 2019. After July 2016, a 25 mg dose of rectal diclofenac was routinely administered within 15 min before ERCP (NSAIDs group, n = 72) and the control group (n = 229) consisted of patients undergoing ERCP before this date without treatment. We compared the incidence of PEP between the two groups using propensity score matching.
Results
A total of 66 pairs of patients in each group were selected. The patients and procedural‐related factors were similar in both groups. In total, 15 patients (11.4%) developed PEP: 12.1% (8/66) in the NSAIDs group and 10.6% (7/66) in the control group (Odds ratio (OR) 1.2; 95% confidence interval (CI) 0.4–3.5; P = 0.78). There was no significant difference in incidence of other adverse events related to ERCP between the two groups.
Conclusions
Prophylactic administration of a 25 mg dose of rectal diclofenac did not reduce the incidence of PEP in patients with a native papilla and a body weight of <50 kg in this study and a certain dose of rectal NSAIDs, such as a 100‐mg dose, should be administered regardless of body weight to prevent PEP.
|
キーワード | diclofenac
low dose
post‐ERCP pancreatitis
|
備考 | This is the peer reviewed version of the following article: Takeshi Tomoda et. al. Efficacy of low dose rectal diclofenac for preventing post‐endoscopic retrograde cholangiopancreatography pancreatitis: Propensity score‐matched analysis. Digestive Endoscopy, which has been published in final form at https://doi.org/10.1111/den.13828. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
|
発行日 | 2020-09-02
|
出版物タイトル |
Digestive Endoscopy
|
巻 | 33巻
|
出版者 | Wiley
|
開始ページ | 656
|
終了ページ | 662
|
ISSN | 0915-5635
|
NCID | AA10907137
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
論文のバージョン | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1111/den.13828
|